- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: SB8: A Bevacizumab Biosimilar ; volume:16 ; number:1 ; day:11 ; month:12 ; year:2020 ; pages:119 ; date:1.2021
Targeted oncology ; 16, Heft 1 (11.12.2020), 119, 1.2021
- Creator
-
Syed, Yahiya Y.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-020-00783-1
- URN
-
urn:nbn:de:101:1-2021030612295925475509
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Syed, Yahiya Y.
- SpringerLink (Online service)
Other Objects (12)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar